Filtered By:
Source: Circulation
Condition: Atrial Fibrillation

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 235 results found since Jan 2013.

The Long Term Multi-Center Observational Study of Dabigatran Treatment in Patients with Atrial Fibrillation: (RELY-ABLE) Study.
CONCLUSIONS: During 2.3 years continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily compared to 110 mg, and similar rates of stroke and death. CLINICAL TRIAL REGISTRATION INFORMATION: Clinicaltrials.gov; Identifier: NCT00808067. PMID: 23770747 [PubMed - as supplied by publisher]
Source: Circulation - June 14, 2013 Category: Cardiology Authors: Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom JW, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn Tags: Circulation Source Type: research

Efficacy and Safety of Dabigatran Compared with Warfarin in Relation to Baseline Renal Function in Patients with Atrial Fibrillation: A RE-LY Trial Analysis.
CONCLUSIONS: The efficacy of both dosages of dabigatran was consistent with the overall trial irrespective of renal function. However, with the CKD-EPI and MDRD equations both dabigatran doses displayed significantly lower rates of major bleeding in patients with GFR ≥80 ml/min. CLINICAL TRIAL REGISTRATION INFORMATION: www.clinicaltrials.gov. Identifier: NCT00262600. PMID: 24323795 [PubMed - as supplied by publisher]
Source: Circulation - December 9, 2013 Category: Cardiology Authors: Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L Tags: Circulation Source Type: research

Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial.
CONCLUSIONS: -GDF-15 is a risk factor for major bleeding, mortality and stroke in atrial fibrillation. The prognostic value for major bleeding and death remained even in the presence of NT-proBNP and hs-TnI. Clinical Trial Registration Information-www.clinicaltrials.gov. Identifier: NCT00412984. PMID: 25294786 [PubMed - as supplied by publisher]
Source: Circulation - October 7, 2014 Category: Cardiology Authors: Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, on behalf of the ARISTOTLE Investigators Tags: Circulation Source Type: research

Clinical Outcomes in 3343 Children and Adults with Rheumatic Heart Disease from 14 Low and Middle Income Countries: 2-Year Follow-up of the Global Rheumatic Heart Disease Registry (the REMEDY study).
CONCLUSIONS: -Patients with clinical RHD have high mortality and morbidity despite being young; those from low and lower-middle income countries had a poorer prognosis associated with advanced disease and low education. Programs focused on early detection and treatment of clinical RHD are required to improve outcomes. PMID: 27702773 [PubMed - as supplied by publisher]
Source: Circulation - October 3, 2016 Category: Cardiology Authors: Zühlke L, Karthikeyan G, Engel ME, Rangarajan S, Mackie P, Cupido B, Mauff K, Islam S, Daniels R, Francis V, Ogendo S, Gitura B, Mondo C, Okello E, Lwabi P, Al-Kebsi MM, Hugo-Hamman C, Sheta SS, Haileamlak A, Daniel W, Goshu DY, Abdissa SG, Desta AG, Sha Tags: Circulation Source Type: research

Subclinical Atrial Fibrillation in Older Patients.
Conclusions -SCAF is frequently detected by continuous electrocardiographic monitoring in older patients without prior history of AF who are attending outpatient cardiology and neurology clinics. Its clinical significance is unclear. Clinical Trial Registration -URL: www.ClinicalTrials.gov Unique Identifier: NCT01694394. PMID: 28778946 [PubMed - as supplied by publisher]
Source: Circulation - August 4, 2017 Category: Cardiology Authors: Healey JS, Alings M, Ha AC, Leong-Sit P, Birnie DH, de Graaf JJ, Freericks M, Verma A, Wang J, Leong D, Dokainish H, Philippon F, Barake W, McIntyre WF, Simek KD, Hill MD, Mehta SR, Carlson M, Smeele F, Pandey AS, Connolly SJ, ASSERT-2 Investigators Tags: Circulation Source Type: research

Efficacy and Safety of Apixaban versus Warfarin in Patients with Atrial Fibrillation and Extremes in Body Weight: Insights from the ARISTOTLE Trial.
CONCLUSIONS: Our findings provide evidence that apixaban is efficacious and safe across the spectrum of weight, including in low (≤60 kg) and high weight patients (>120 kg). The superiority on efficacy and safety outcomes of apixaban compared with warfarin persists across weight groups, with even greater reductions in major bleeding in patients with AF with low-normal weight as compared with high weight. The superiority of apixaban over warfarin in regard to efficacy and safety for stroke prevention seems to be similar in patients with AF across the spectrum of weight, including in the low and very high weight patient...
Source: Circulation - February 18, 2019 Category: Cardiology Authors: Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD Tags: Circulation Source Type: research

A Comprehensive Evaluation of Rhythm Monitoring Strategies in Screening for Atrial Fibrillation: Insights from Patients at Risk Long-Term Monitored with Implantable Loop Recorder.
Conclusions: In screening for AF among participants with stroke risk factors, the diagnostic yield increased with duration, dispersion and number of screenings, although all strategies had low yield compared to ILR. The sensitivity was higher among participants who were older, males, or had higher NT-proBNP. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02036450. PMID: 32114796 [PubMed - as supplied by publisher]
Source: Circulation - March 1, 2020 Category: Cardiology Authors: Diederichsen SZ, Haugan KJ, Kronborg C, Graff C, Højberg S, Køber L, Krieger D, Holst AG, Nielsen JB, Brandes A, Svendsen JH Tags: Circulation Source Type: research

Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex
Conclusions: Compared with warfarin, DOACs have more favorable efficacy and safety profiles among patients with AF.PMID:34985309 | DOI:10.1161/CIRCULATIONAHA.121.056355
Source: Circulation - January 5, 2022 Category: Cardiology Authors: Anthony P Carnicelli Hwanhee Hong Stuart J Connolly John Eikelboom Robert P Giugliano David A Morrow Manesh R Patel Lars Wallentin John H Alexander M Cecilia Bahit Alexander P Benz Erin A Bohula Tze-Fan Chao Leanne Dyal Michael Ezekowitz Keith Aa Fox Bari Source Type: research

Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden
CONCLUSIONS: Patients with recently diagnosed atrial fibrillation and CHA2DS2-VASc score ≥4 should be considered for ERC to reduce cardiovascular outcomes, whereas those with fewer comorbidities may have less favorable outcomes with ERC.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01288352; URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2010-021258-20; URL: https://www.isrctn.com/; Unique identifier: ISRCTN04708680.PMID:35968706 | DOI:10.1161/CIRCULATIONAHA.122.060274
Source: Circulation - August 15, 2022 Category: Cardiology Authors: Andreas Rillig Katrin Borof G ünter Breithardt A John Camm Harry J G M Crijns Andreas Goette Karl-Heinz Kuck Andreas Metzner Panos Vardas Eik Vettorazzi Karl Wegscheider Antonia Zapf Paulus Kirchhof Source Type: research

Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial
CONCLUSIONS: There was inadequate power to draw any conclusion regarding rates of major or clinically relevant non-major bleeding comparing apixaban and warfarin in patients with AF and ESKD on hemodialysis. Clinically relevant bleeding events were approximately 10-fold more frequent than stroke or systemic embolism among this population on anticoagulation, highlighting the need for future randomized studies evaluating the risks versus benefits of anticoagulation among patients with AF and ESKD on hemodialysis.PMID:36335914 | DOI:10.1161/CIRCULATIONAHA.121.054990
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Sean D Pokorney Glenn M Chertow Hussein R Al-Khalidi Dianne Gallup Pat Dignaco Kurt Mussina Nisha Bansal Crystal A Gadegbeku David A Garcia Samira Garonzik Renato D Lopes Kenneth W Mahaffey Kelly Matsuda John P Middleton Jennifer A Rymer George H Sands Ra Source Type: research

Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International Collaboration
Circulation. 2022 Nov 8;146(19):1461-1474. doi: 10.1161/CIRCULATIONAHA.121.058911. Epub 2022 Nov 7.ABSTRACTThe technological evolution and widespread availability of wearables and handheld ECG devices capable of screening for atrial fibrillation (AF), and their promotion directly to consumers, has focused attention of health care professionals and patient organizations on consumer-led AF screening. In this Frontiers review, members of the AF-SCREEN International Collaboration provide a critical appraisal of this rapidly evolving field to increase awareness of the complexities and uncertainties surrounding consumer-led AF s...
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Axel Brandes Stavros Stavrakis Ben Freedman Sotiris Antoniou Giuseppe Boriani A John Camm Clara K Chow Eric Ding Johan Engdahl Michael M Gibson Gregory Golovchiner Taya Glotzer Yutao Guo Jeff S Healey Mellanie T Hills Linda Johnson Gregory Y H Lip Trudie Source Type: research